Month: June 2023

DISRUPTIVE CAPITAL ACQUISITION COMPANY LIMITED(“DCAC” or the “Company”) in respect ofDCAC Shareholders (ISIN Code GG00BMB5XZ39) and DCAC Public Warrant Holders (ISIN Code GG00BMB5XY22) Listing as Global InterConnection Group as of 7 July 2023 30 June 2023 Please refer to the attached press release. Attachment20230630 DCAC-Global InterConnection Group Press Release – final version

Logent Group has today entered into an agreement with KH Group to acquire all shares in the Finnish company Logistikas Oy (“Logistikas”). The debt-free purchase price of the share transaction is EUR 23.5 million and the total purchase price paid to the sellers for the shares and other equity items is approximately EUR 18.5 million. In 2022, Logistikas’ net sales amounted to EUR 31.8 million and EBITDA to EUR 2.4 million. The acquisition is not subject to any conditions and the closing takes effect immediately. Logistikas has a strong reputation and a solid client base in contract logistics, including both dedicated solutions, a complementary multi-client warehousing offering and transport management services. Being present in the western and central parts of Finland, Logistikas is strategically positioned for further growth and will be...

KH Group PlcInside information 30 June 2023 at 5:30 pm EEST Inside information: KH Group sells the logistics service company Logistikas As part of its strategic transformation, KH Group Plc has today, on 30 June 2023, together with the other shareholders of Logistikas Oy, sold the shares of Logistikas Oy to the Swedish logistics company Logent AB. The transaction was signed and completed simultaneously. The debt-free purchase price of the share transaction is EUR 23.5 million. KH Group’s holding in Logistikas was 66.5% and its share of the purchase price, after the deduction of net debt and transaction costs, is approximately EUR 11.9 million, including the purchase price for the shares and for the receivables from Logistikas Oy related to dividend and capital distribution in conjunction with the transaction. The final purchase price will...

Special Committee Continues to Actively Evaluate Unsolicited Proposal from Lucy Scientific Discovery Inc. PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, confirms its Board of Directors (“Board”) has previously formed a special committee of independent and disinterested directors (the “Special Committee”) to assess an unsolicited proposal from Lucy Scientific Discovery Inc. (NASDAQ: LSDI) (“Lucy”) to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock. Consistent with its fiduciary obligations...

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its Phase IIb clinical trial to use SCI-110 for treating adults with Tourette Syndrome (“TS”) at the Hannover Medical School in Hannover, Germany. The Phase IIb clinical trial will be conducted at three global leading centers of excellence: the Yale Child Study Center...

-Improvements in Left Ventricular Ejection Fraction (LVEF) for the Majority of Patients Suggest Preservation of Cardiac Function- -Results in Performance of the Upper Limb PUL v2.0 Continue to Show Long-Term Benefit in Skeletal Muscle Function (p=0.02)- -Safety and Efficacy Results Continue to Suggest Potential Disease Attenuation in Duchenne Muscular Dystrophy (DMD)- -Results to be Presented at the PPMD Annual Conference Being Held Today- SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced positive 24-month safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study with its lead asset,...